Delivery Order SPE2DB24D3013-SPE2DB26FFFNM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 units, with a ceiling value of $18,754.48. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 10, 2025. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 16 units, with a ceiling value of $1,623.12. This is a firm fixed price delivery order under an Indefinite Delivery Contract with no set-aside designation, reflecting a competitively awarded procurement. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $16,523.11 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (16 count) on September 16, 2025, with completion expected by September 17, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order contract for UBRELVY 100 mg tablets (16-count unit dose packages) on September 9, 2025, with a contract ceiling value of $1,252.24 and ultimate completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement. The work is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and represents a...
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,856.58 to AmerisourceBergen Drug Corp for UBRELVY 50 MG tablets (10 unit doses) on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract under the company's broader pharmaceutical supply agreement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $4,338.57 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging, quantities of 16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and was competitively awarded without set-aside designation. The pharmaceutical will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB26FFFNMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $12,477.70 to supply UBRELVY 100 mg tablets in unit dose packaging (16-count). The contract was competitively awarded without set-aside restrictions on October 16, 2025, with an ultimate completion date of October 17, 2025. AmerisourceBergen will perform the work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is priced on a firm fixed-price basis, consistent with the company's standard federal procurement arrangements. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive pharmaceutical supply vehicle enabling AmerisourceBergen to deliver a broad range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs globally. UBRELVY (ubrogepant), a migraine treatment medication, represents one component of the extensive pharmaceutical portfolio the company supplies to the Defense Health Agency and other federal healthcare systems through this vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 10/16/25 |